Skip to content

A Randomized Controlled Clinical Study on Treatment of Acute Simple Urinary Tract Infection of Xiajiao Damp-Heat Type with Niaogan Fang

A Randomized Controlled Clinical Study on Treatment of Acute Simple Urinary Tract Infection of Xiajiao Damp-Heat Type with Niaogan Fang

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000004035
Enrollment
Unknown
Registered
2020-08-29
Start date
2020-11-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infection

Interventions

Sponsors

Shanghai Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 50 years old; (2) Meet the Western diagnostic criteria for UTI under acute uncomplicated conditions, that is, the duration of the disease does not exceed 72 hours; (3) The result of bacterial culture is levofloxacin sensitive (bacterial culture and clinical treatment will be carried out at the same time); (4) TCM differentiation is Xiajiao damp-heat syndrome; (5) Did not receive antibiotic treatment within 48 hours before being selected; (6) Not pregnant or breastfeeding; (7) Sign the written informed consent of the clinical trial.

Exclusion criteria

Exclusion criteria: (1) Allergy to test drugs or quinolones; (2) Have a history of bacterial culture that is not sensitive to levofloxacin; (3) Diagnosed as complicated UTI disease; (4) Patients suffering from urinary calculi or obstruction, urinary tuberculosis, renal papillary necrosis, perinephric abscess or neurogenic bladder; (5) Accompanied by symptoms of vaginitis, genital ulcers or gonorrhea; (6) Combined with severe heart and lung disease, liver and kidney disease, advanced tumor and other serious or progressive diseases; (7) Suffer from neurological or mental illness, unable to cooperate; (8) Combined use of other antibacterial drugs; (9) Women who are pregnant, breastfeeding, or planning to become pregnant; (10) Participate in another clinical trial within three months before being selected.

Design outcomes

Primary

MeasureTime frame
Actual efficiency;Urine routine;

Secondary

MeasureTime frame
Recurrence rate;

Countries

China

Contacts

Public ContactWu Yu
hongshucc@126.com+86 19821855530

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026